Active Recombinant Human S100A9 protein

• Cat.No.: S100A9-255H
• Product Overview: Recombinant Human S100A9(Thr2-Pro114) was expressed in E. coli.

Specification

• Description: S100A9, also known as MRP14 and Calgranulin B, is an approximately 14 kDa pro-inflammatory protein in the S100 family of calcium binding proteins. It is up-regulated in neutrophils and monocytes at sites of inflammation (e.g. psoriasis, rheumatoid arthritis, cardiac ischemia) and is present at elevated concentrations in rheumatoid arthritis synovial fluid. Human S100A9 contains two EF-hand calcium binding motifs and shares 57% and 62% amino acid sequence identity with mouse and rat S100A9, respectively. S100A9 is a noncovalent homodimer that can also noncovalently heterodimerize with S100A8; in the presence of calcium and zinc, the homodimer and heterodimers will form tetramers. Human S100A9 can be phosphorylated at Thr113 near the C-terminus, a residue which is not conserved in the mouse protein. Human S100A9 can also be modified by S-glutathionylation and oxidation. The S100A8/A9 heterodimer binds to fatty acids such as arachidonic acid, while neither monomer does. S100A9 and the heterodimer promote neutrophil infiltration and degranulation at sites of inflammation and inflammatory cytokine production by monocytes. S100A9 also promotes cartilage matrix destruction in osteoarthritis as well as RAGE-dependent cardiac fibrosis and remodeling. In the brain, the S100A9 homodimer promotes neuronal cytotoxicity, although this is reduced by its binding to amyloid-beta peptide.
• Source: E. coli
• Species: Human
• Predicted N Terminal: Thr2
• Form: Lyophilized from a 0.2 μm filtered solution in Tris, TCEP and Trehalose.
• Bio-activity: Measured by its ability to induce CXCL1/KC secretion by C3H10T1/2 mouse embryonic fibroblast cells. The ED50 for this effect is 0.8-4 μg/mL.
• Molecular Mass: Predicted Molecular Mass: 13 kDa
  SDS-PAGE: 12 kDa, reducing conditions
• Endotoxin: <0.1 EU per 1 μg of the protein by the LAL method.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 centigrade as supplied.
  1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
  3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
• Reconstitution: Reconstitute at 400 μg/mL in water.
• Tag: Non
• Protein length: Thr2-Pro114

Gene Information

• Gene Name: S100A9 S100 calcium binding protein A9 [ Homo sapiens ]
• Official Symbol: S100A9
• Synonyms: S100A9; S100 calcium binding protein A9; CAGB, CFAG, S100 calcium binding protein A9 (calgranulin B) , S100 calcium binding protein A9 (calgranulin B); protein S100-A9; 60B8AG; CGLB; LIAG; MAC387; MIF; MRP14; NIF; P14; MRP-14; calgranulin B; calgranulin-B; calprotectin L1H subunit; leukocyte L1 complex heavy chain; migration inhibitory factor-related protein 14; S100 calcium-binding protein A9 (calgranulin B); CAGB; CFAG; L1AG
• Gene ID: 6280
• mRNA Refseq: NM_002965
• Protein Refseq: NP_002956
• MIM: 123886
• UniProt ID: P06702

Reviews

08/17/2021

This includes complementary reagents, protocols, and access to an extensive knowledge base, all aimed at streamlining the trial process and maximizing the chances of achieving meaningful results.

06/20/2016

By choosing the S100A9 protein and partnering with the manufacturer, researchers can confidently conduct their trials, achieve reliable results, and contribute to groundbreaking discoveries.

04/04/2016

Collaborating with the manufacturer opens up possibilities for potential collaboration and exchange of information with a wider scientific community, allowing researchers to stay at the forefront of advancements in their respective fields.

Q&As

How is S100A9 protein measured in clinical settings?

S100A9 levels can be measured using various laboratory techniques, such as ELISA (enzyme-linked immunosorbent assay).

Are there any therapies or drugs targeting S100A9 in clinical development?

Some research is exploring the development of drugs that target S100A9 to modulate inflammation, but clinical applications are still in the experimental phase.

Can S100A9 levels be used as a biomarker for specific diseases?

Yes, elevated S100A9 levels have been associated with conditions like rheumatoid arthritis and inflammatory bowel disease, making it a potential biomarker.

Can S100A9 be used to predict disease outcomes?

Elevated S100A9 levels have been linked to poorer outcomes in certain diseases, making it a potential predictor of disease severity.

Are there any genetic factors that influence S100A9 levels?

Genetic variations can influence S100A9 expression, and these variations may impact an individual's susceptibility to certain diseases.